# MAJOR MILESTONE - FIRST PATIENT ENROLLED IN DIAGNOSTIC TRIALS | Eliaz Therapeutics

- Canonical URL: https://wefunder.com/feed/184178
- Entity ID: wefunder:feed_item:184178
- Published at: 2025-07-28 21:55:55 UTC
- Updated at: 2025-07-29 06:09:33 UTC

## Author
Dr. Isaac Eliaz (MD)

## Subject
Eliaz Therapeutics

## Content
Dear Eliaz Therapeutics followers & investor,I am deeply humbled to announce that we’ve officially enrolled the first patient in our diagnostic clinical study at Tel Aviv Sourasky (Ichilov) Medical Center, a hospital ranked among the world's very best.This means that for the first time ever, we will systematically monitor the real-time level of Galectin-3 in critically ill sepsis patients during their ICU stay. By tracking these Galectin-3 dynamics, we aim to uncover the precise patterns that predict organ failure or recovery. This will provide us with the crucial insights needed to optimize our XGal-3® therapy to know exactly when to intervene for maximum life-saving impact.This single patient, and those who will follow, represent the first chapter in a new story for critical care. It's a story where we don't just manage symptoms, but target the root cause of the inflammatory cascade.This historic milestone is a testament to our team’s tireless work and to your unwavering belief in our vision. Together, we are changing the future of critical care!Yours in health,Isaac Eliaz, MD, MS, LAc💡 Ready to join the fight against sepsis? Invest today.